<DOC>
	<DOCNO>NCT00004858</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient recurrent acute lymphoblastic leukemia non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Recurrent Acute Lymphoblastic Leukemia Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose B43-genistein immunoconjugate patient recurrent B-cell acute lymphoblastic leukemia non-Hodgkin 's lymphoma . II . Determine systemic B43-genistein exposure level patient . III . Determine antileukemic activity regimen patient . IV . Monitor development human antimouse antibody patient regimen . OUTLINE : This dose escalation study . Patients receive B43-genistein immunoconjugate IV 1 hour day 1-3 , 8-10 , 15-17 . Treatment continue every 3 week absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos B43-genistein immunoconjugate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow every 6 month . PROJECTED ACCRUAL : A minimum 3-15 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Immunophenotypically proven Bcell acute lymphoblastic leukemia Relapsed least follow standard induction chemotherapy M1 , M2 , M3 No CNS disease ( include clinical sign CNS disease ) OR Immunophenotypically proven Bcell nonHodgkin 's lymphoma Refractory resistant disease follow 3 prior course combination chemotherapy Relapsed follow bone marrow transplantation No CNS disease No AIDSrelated HTLV1 associate lymphomas NHL must one follow type : Small lymphocytic lymphoma ( consistent chronic lymphoblastic leukemia ) Follicular small cleave cell lymphoma Follicular mix cell lymphoma Follicular large cell lymphoma Diffuse small cleave cell lymphoma Diffuse mix cell lymphoma Diffuse large cell lymphoma Immunoblastic large cell lymphoma Diffuse small noncleaved cell lymphoma Must great 20 % CD19 antigen positive blast bone marrow , peripheral blood , biopsy ( NHL ) first diagnosis relapse ( nonT cell ALL CD19 positivity pending allow ) Patients relapse bone marrow transplantation eligible ( active acute chronic graft versus host disease involve skin ) PATIENT CHARACTERISTICS : Age : 80 Performance status : Karnofsky 60100 % Zubrod 02 Life expectancy : At least 2 month Hematopoietic : Granulocytopenia , anemia , and/or thrombocytopenia allow Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN Renal : Creatinine great 1.5 time ULN OR Creatinine clearance radioisotope GFR least 70 mL/min Cardiovascular : Shortening fraction least 27 % echocardiogram OR Cardiac ejection fraction great 50 % echocardiogram gaited radionuclide Pulmonary : No dyspnea rest No exercise intolerance No clinical evidence significant restrictive pulmonary disease Pulse oximetry great 94 % FEV1 FVC great 60 % DLCO least 65 Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study HIV negative No uncontrolled diabetes mellitus No serious uncontrolled medical condition No active uncontrolled infection require systemic antibiotic antifungal medication Prior CNS toxicity great grade 1 PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Recovered prior biologic therapy Chemotherapy : See Disease Charactertistics At least 2 week since prior chemotherapy ( 4 week since nitrosoureas ) recover Endocrine therapy : At least 1 week since prior high dose steroid therapy recover Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>